Phase 2 N=42 Chemoprevention Trial - Anastrozole in Ductal Carcinoma In Situ (DCIS) in Postmenopausal Women
DCIS
Primary: Number of Participants With a Change in Ki-67 Level — 15; 5; 3 Participants — p=0.004
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=24 A Study Called ARAMON to Learn to What Extent Does Study Treatment With Darolutamide Affects Testosterone Levels in Men With Prostate Cancer That Had Not Been Treated With Hormonal Therapy Compared to Treatment With Enzalutamide
Biochemically Recurrent Prostate Cancer
Primary: Percent Change in Serum Testosterone — 53.46 percentage (%)
N/A N=54 External-Beam Partial-Breast Irradiation for Early Breast Cancer 40 Gy QD Over 2 Weeks
Breast Cancer
Primary: Safety of External-beam PBI Utilizing 40Gy in Ten Daily Fractions Over Two Weeks — 0; 0; 0; 0 Participants
Phase 2 N=24 Novel Capecitabine Dosing Schedule in Combination With Lapatinib, Based on the Norton-Simon Mathematical Method in Patients With HER2 Overexpressed/Amplified, Trastuzumab (Herceptin) -Refractory, Metastatic Breast Cancer
Breast Cancer
Primary: Estimate Efficacy of Capecitabine 7/7 in Combination With Lapatinib in Patients With HER2 Overexpressed/Amplified, Trastuzumab-refractory, Metastatic Breast Cancer as…
Phase 2 N=50 Simvastatin in Preventing a New Breast Cancer in Women at High Risk for a New Breast Cancer
Breast Cancer
Primary: Change in a Panel of Biomarkers (High-sensitivity C-reactive Protein [hsCRP], Lipid Profile, and Circulating Estrogens) From Baseline — -0.15; -54; -1; -81.5 mg/dl
N/A N=198 One-stage Breast Reconstruction Using Dermal Matrix/Implant Versus Two-stage Expander/Implant Procedure
Breast Cancer
Primary: BreastQ Quality of Life and Satisfaction Questionnaire — 65.32; 67.07 score on a scale — p=0.05
N/A N=180 Early Initiation of Milk Expression in Mothers of Very Low Birth Weight Infants
Breast Milk Expression
Primary: Pumped Milk Volume Day 1 — 3; 4; 5 mL — p=0.015
Phase 3 N=131 Botulinum Toxin A (Botox) in Tissue Expander Breast Reconstruction
Breast Cancer · Pain, Postoperative · BRCA1 Mutation
Primary: Change From Baseline in Average Pain Scores Using a Numeric Pain Intensity Scale — 2; 3 score on a scale — p=0.43
Phase 2 N=72 Arimidex With or Without Faslodex In Postmenopausal Women With HR Positive Breast Cancer
Breast Cancer
Primary: Change in Ki-67 Levels From Baseline (Pre) to Day 28 (Post) Biopsy Samples — -1.3632; -1.6237 log-transformed Ki67% — p=0.6202
N/A N=9 Etravirine Pharmacokinetics and HIV Viral Load in Breast Milk and Plasma
HIV
Primary: Peak Plasma Concentration of Etravirine in Plasma — 497.6 ng/ml
Phase 2 N=512 T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Breast Cancer
Primary: Number of Participants of Clinically Relevant Toxicities (CRT) — 36; 13; 42; 26 Participants
Phase 2 N=64 Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer
Breast Cancer · Triple Negative Breast Cancer · Stage IV Breast Cancer
Primary: Objective Response Rate — 28; 38 percentage of patients
N/A N=50 Single Fraction High-Gradient Partial Breast Irradiation in Treating Patients With Low-Risk Stage 0-I Breast Cancer
Breast Neoplasms
Primary: Percentage of Patients Who Are Free of Serious Treatment Related Toxicity — 50; 49 Participants
N/A N=271 Promoting Breast Cancer Screening in Women Who Survived Childhood Cancer
Breast Neoplasms · Early Detection of Cancer
Primary: Percentage of Women Who Completed a Breast MRI and Mammogram — 8.9; 22.0; 17.8 percentage of participants — p=0.019
N/A N=51 Psychosocial Outcomes in Online Cancer Support Groups
Breast Cancer
Primary: Scores on the Personal Resource Questionnaire 85. — 50.22; 53.44 Scores on a scale — p=.315